{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:35Z","timestamp":1793726015448,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T00:00:00Z","timestamp":1515628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T00:00:00Z","timestamp":1515628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although autoimmune hepatitis (AIH) can be treated with corticosteroid-based first-line therapy, incomplete remission is associated with progressive liver fibrosis. So far accepted predictors of the subsequent treatment response of AIH patients are lacking. Therefore, we analysed baseline parameters, including iron homeostasis and cytokine levels, in 60 children with paediatric AIH (pAIH). In contrast to adults, elevated serum markers indicating iron overload were not commonly found in children. Therefore, ferritin was not predictive of the treatment response in pAIH. Although baseline immunoglobulins were lower in pAIH children with subsequent complete biochemical remission (BR) upon standard first-line therapy, only lower AIH scores (\u226416 points) could predict BR upon standard therapy in our training and validation cohorts. Additionally, higher baseline IL-2 and MCP-1\/CCL2 levels were associated with BR in a sub-cohort. A combined score of IL-2 level and a simplified AIH score predicted treatment response more precisely than both parameter alone in this sub-cohort. In conclusion, the baseline AIH score could be validated as a predictor of treatment response in pAIH. Additionally, low baseline IL-2 may help identify children who need salvage therapy. This could be important because the use of low-dose IL-2 therapies is being tested in various autoimmune diseases.<\/jats:p>","DOI":"10.1038\/s41598-017-18818-5","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T10:04:04Z","timestamp":1515146644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis"],"prefix":"10.1038","volume":"8","author":[{"given":"Jana","family":"Diestelhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Jonigk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Schlue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Jaeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Taubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,11]]},"reference":[{"key":"18818_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","volume":"60","author":"L Gronbaek","year":"2014","unstructured":"Gronbaek, L., Vilstrup, H. & Jepsen, P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 60, 612\u2013617, https:\/\/doi.org\/10.1016\/j.jhep.2013.10.020 (2014).","journal-title":"J Hepatol"},{"key":"18818_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jaut.2013.08.004","volume":"46","author":"A Floreani","year":"2013","unstructured":"Floreani, A., Liberal, R., Vergani, D. & Mieli-Vergani, G. Autoimmune hepatitis: Contrasts and comparisons in children and adults - a comprehensive review. J Autoimmun 46, 7\u201316, https:\/\/doi.org\/10.1016\/j.jaut.2013.08.004 (2013).","journal-title":"J Autoimmun"},{"key":"18818_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00431-015-2662-x","volume":"175","author":"N Junge","year":"2016","unstructured":"Junge, N. et al. Human leucocyte antigens and pediatric autoimmune liver disease: diagnosis and prognosis. Eur J Pediatr 175, 527\u2013537, https:\/\/doi.org\/10.1007\/s00431-015-2662-x (2016).","journal-title":"Eur J Pediatr"},{"key":"18818_CR4","doi-asserted-by":"publisher","unstructured":"Kirstein, M. M. et al. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology, https:\/\/doi.org\/10.1002\/hep.27983 (2015).","DOI":"10.1002\/hep.27983"},{"key":"18818_CR5","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/hep.26290","volume":"57","author":"JH Ngu","year":"2013","unstructured":"Ngu, J. H., Gearry, R. B., Frampton, C. M. & Stedman, C. A. Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study. Hepatology 57, 2399\u20132406, https:\/\/doi.org\/10.1002\/hep.26290 (2013).","journal-title":"Hepatology"},{"key":"18818_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1053\/jhep.2001.22131","volume":"33","author":"GV Gregorio","year":"2001","unstructured":"Gregorio, G. V. et al. Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33, 544\u2013553, https:\/\/doi.org\/10.1053\/jhep.2001.22131 (2001).","journal-title":"Hepatology"},{"key":"18818_CR7","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","volume":"139","author":"MP Manns","year":"2010","unstructured":"Manns, M. P. et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 139, 1198\u20131206, https:\/\/doi.org\/10.1053\/j.gastro.2010.06.046 (2010).","journal-title":"Gastroenterology"},{"key":"18818_CR8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jpeds.2013.05.042","volume":"163","author":"M Woynarowski","year":"2013","unstructured":"Woynarowski, M. et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr 163, 1347\u20131353 e1341, https:\/\/doi.org\/10.1016\/j.jpeds.2013.05.042 (2013).","journal-title":"J Pediatr"},{"key":"18818_CR9","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns, M. P. et al. Diagnosis and management of autoimmune hepatitis. Hepatology 51, 2193\u20132213, https:\/\/doi.org\/10.1002\/hep.23584 (2010).","journal-title":"Hepatology"},{"key":"18818_CR10","doi-asserted-by":"crossref","unstructured":"Muratori, L., Muratori, P., Lanzoni, G., Ferri, S. & Lenzi, M. Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology 52, 1857; author reply 1857-1858 (2010).","DOI":"10.1002\/hep.23924"},{"key":"18818_CR11","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jhep.2009.01.020","volume":"50","author":"P Muratori","year":"2009","unstructured":"Muratori, P. et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 50, 1210\u20131218 (2009).","journal-title":"J Hepatol"},{"key":"18818_CR12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/ajg.2015.139","volume":"110","author":"HK Dhaliwal","year":"2015","unstructured":"Dhaliwal, H. K. et al. Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis. The American journal of gastroenterology 110, 993\u2013999, https:\/\/doi.org\/10.1038\/ajg.2015.139 (2015).","journal-title":"The American journal of gastroenterology"},{"key":"18818_CR13","doi-asserted-by":"publisher","first-page":"e0179074","DOI":"10.1371\/journal.pone.0179074","volume":"12","author":"R Taubert","year":"2017","unstructured":"Taubert, R. et al. Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis. PloS one 12, e0179074, https:\/\/doi.org\/10.1371\/journal.pone.0179074 (2017).","journal-title":"PloS one"},{"key":"18818_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/ejh.12081","volume":"90","author":"G Cangemi","year":"2013","unstructured":"Cangemi, G. et al. Diagnostic potential of hepcidin testing in pediatrics. Eur J Haematol 90, 323\u2013330, https:\/\/doi.org\/10.1111\/ejh.12081 (2013).","journal-title":"Eur J Haematol"},{"key":"18818_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/jcla.21719","volume":"29","author":"T Sdogou","year":"2015","unstructured":"Sdogou, T. et al. Immunoassay-based serum hepcidin reference range measurements in healthy children: differences among age groups. J Clin Lab Anal 29, 10\u201314, https:\/\/doi.org\/10.1002\/jcla.21719 (2015).","journal-title":"J Clin Lab Anal"},{"key":"18818_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/hep.25615","volume":"56","author":"JB Goodnough","year":"2012","unstructured":"Goodnough, J. B., Ramos, E., Nemeth, E. & Ganz, T. Inhibition of hepcidin transcription by growth factors. Hepatology 56, 291\u2013299, https:\/\/doi.org\/10.1002\/hep.25615 (2012).","journal-title":"Hepatology"},{"key":"18818_CR17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez, F. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31, 929\u2013938 (1999).","journal-title":"J Hepatol"},{"key":"18818_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes, E. M. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48, 169\u2013176, https:\/\/doi.org\/10.1002\/hep.22322 (2008).","journal-title":"Hepatology"},{"key":"18818_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/eci.12032","volume":"43","author":"C Datz","year":"2013","unstructured":"Datz, C., Felder, T. K., Niederseer, D. & Aigner, E. Iron homeostasis in the metabolic syndrome. Eur J Clin Invest 43, 215\u2013224, https:\/\/doi.org\/10.1111\/eci.12032 (2013).","journal-title":"Eur J Clin Invest"},{"key":"18818_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.autrev.2007.01.016","volume":"6","author":"G Zandman-Goddard","year":"2007","unstructured":"Zandman-Goddard, G. & Shoenfeld, Y. Ferritin in autoimmune diseases. Autoimmunity reviews 6, 457\u2013463, https:\/\/doi.org\/10.1016\/j.autrev.2007.01.016 (2007).","journal-title":"Autoimmunity reviews"},{"key":"18818_CR21","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/liv.13369","volume":"37","author":"OE Anastasiou","year":"2017","unstructured":"Anastasiou, O. E. et al. Low transferrin and high ferritin concentrations are associated with worse outcome in acute liver failure. Liver international: official journal of the International Association for the Study of the Liver 37, 1032\u20131041, https:\/\/doi.org\/10.1111\/liv.13369 (2017).","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"key":"18818_CR22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/clinchem\/46.6.885","volume":"46","author":"CI Bhagat","year":"2000","unstructured":"Bhagat, C. I., Fletcher, S., Joseph, J. & Beilby, J. P. Plasma ferritin in acute hepatocellular damage. Clin Chem 46, 885\u2013886 (2000).","journal-title":"Clin Chem"},{"key":"18818_CR23","doi-asserted-by":"publisher","unstructured":"Zizzo, A. N. et al. A national retrospective study of paediatric end-stage liver disease as a predictor of change to second-line therapy in children with autoimmune hepatitis. Liver international: official journal of the International Association for the Study of the Liver, https:\/\/doi.org\/10.1111\/liv.13387 (2017).","DOI":"10.1111\/liv.13387"},{"key":"18818_CR24","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1093\/bioinformatics\/btv309","volume":"31","author":"L Kuchenbecker","year":"2015","unstructured":"Kuchenbecker, L. et al. IMSEQ\u2013a fast and error aware approach to immunogenetic sequence analysis. Bioinformatics 31, 2963\u20132971, https:\/\/doi.org\/10.1093\/bioinformatics\/btv309 (2015).","journal-title":"Bioinformatics"},{"key":"18818_CR25","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1053\/j.gastro.2011.02.010","volume":"140","author":"AJ Czaja","year":"2011","unstructured":"Czaja, A. J. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology 140, 1472\u20131480, https:\/\/doi.org\/10.1053\/j.gastro.2011.02.010 (2011).","journal-title":"Gastroenterology"},{"key":"18818_CR26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1053\/jhep.2002.32485","volume":"35","author":"AJ Czaja","year":"2002","unstructured":"Czaja, A. J., Menon, K. V. & Carpenter, H. A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 35, 890\u2013897, https:\/\/doi.org\/10.1053\/jhep.2002.32485 (2002).","journal-title":"Hepatology"},{"key":"18818_CR27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1572-0241.2007.01153.x","volume":"102","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza, A. J., Carpenter, H. A. & Czaja, A. J. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. The American journal of gastroenterology 102, 1005\u20131012, https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01153.x (2007).","journal-title":"The American journal of gastroenterology"},{"key":"18818_CR28","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","volume":"99","author":"S Verma","year":"2004","unstructured":"Verma, S., Gunuwan, B., Mendler, M., Govindrajan, S. & Redeker, A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. The American journal of gastroenterology 99, 1510\u20131516, https:\/\/doi.org\/10.1111\/j.1572-0241.2004.30457.x (2004).","journal-title":"The American journal of gastroenterology"},{"key":"18818_CR29","doi-asserted-by":"publisher","first-page":"682","DOI":"10.5604\/16652681.1212319","volume":"15","author":"BE Behairy","year":"2016","unstructured":"Behairy, B. E. et al. Assessment of intrahepatic regulatory T cells in children with autoimmune hepatitis. Annals of hepatology 15, 682\u2013690, https:\/\/doi.org\/10.5604\/16652681.1212319 (2016).","journal-title":"Annals of hepatology"},{"key":"18818_CR30","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.4049\/jimmunol.0901216","volume":"184","author":"YH Oo","year":"2010","unstructured":"Oo, Y. H. et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol 184, 2886\u20132898, https:\/\/doi.org\/10.4049\/jimmunol.0901216 (2010).","journal-title":"J Immunol"},{"key":"18818_CR31","doi-asserted-by":"publisher","unstructured":"Chen, Y. Y. et al. Human intrahepatic tregs are functional, require IL-2 from effector cells for survival and are susceptible to fas ligand mediated apoptosis. Hepatology, https:\/\/doi.org\/10.1002\/hep.28517 (2016).","DOI":"10.1002\/hep.28517"},{"key":"18818_CR32","doi-asserted-by":"publisher","first-page":"e0181107","DOI":"10.1371\/journal.pone.0181107","volume":"12","author":"J Diestelhorst","year":"2017","unstructured":"Diestelhorst, J. et al. Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy. PloS one 12, e0181107, https:\/\/doi.org\/10.1371\/journal.pone.0181107 (2017).","journal-title":"PloS one"},{"key":"18818_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 1, 295\u2013305, https:\/\/doi.org\/10.1016\/S2213-8587(13)70113-X (2013).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"18818_CR34","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365, 2055\u20132066, https:\/\/doi.org\/10.1056\/NEJMoa1108188 (2011).","journal-title":"N Engl J Med"},{"key":"18818_CR35","doi-asserted-by":"publisher","first-page":"179ra143","DOI":"10.1126\/scitranslmed.3005265","volume":"5","author":"K Matsuoka","year":"2013","unstructured":"Matsuoka, K. et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 5, 179ra143, https:\/\/doi.org\/10.1126\/scitranslmed.3005265 (2013).","journal-title":"Sci Transl Med"},{"key":"18818_CR36","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun, D. et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365, 2067\u20132077, https:\/\/doi.org\/10.1056\/NEJMoa1105143 (2011).","journal-title":"N Engl J Med"},{"key":"18818_CR37","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","volume":"75","author":"C von Spee-Mayer","year":"2016","unstructured":"von Spee-Mayer, C. et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis 75, 1407\u20131415, https:\/\/doi.org\/10.1136\/annrheumdis-2015-207776 (2016).","journal-title":"Ann Rheum Dis"},{"key":"18818_CR38","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/hep.510240619","volume":"24","author":"HF Lohr","year":"1996","unstructured":"Lohr, H. F. et al. Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis. Hepatology 24, 1416\u20131421, https:\/\/doi.org\/10.1002\/hep.510240619 (1996).","journal-title":"Hepatology"},{"key":"18818_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/liv.12245","volume":"34","author":"L Ma","year":"2014","unstructured":"Ma, L., Qin, J., Ji, H., Zhao, P. & Jiang, Y. Tfh and plasma cells are correlated with hypergammaglobulinaemia in patients with autoimmune hepatitis. Liver international: official journal of the International Association for the Study of the Liver 34, 405\u2013415 (2014).","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"key":"18818_CR40","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jhep.2014.05.034","volume":"61","author":"R Taubert","year":"2014","unstructured":"Taubert, R. et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol 61, 1106\u20131114, https:\/\/doi.org\/10.1016\/j.jhep.2014.05.034 (2014).","journal-title":"J Hepatol"},{"key":"18818_CR41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/hep.27306","volume":"61","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. CXCR5+ CD46+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology 61, 627\u2013638, https:\/\/doi.org\/10.1002\/hep.27306 (2015).","journal-title":"Hepatology"},{"key":"18818_CR42","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the, L. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 63, 971-1004, https:\/\/doi.org\/10.1016\/j.jhep.2015.06.030 (2015).","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"18818_CR43","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/hep.1840180613","volume":"18","author":"YM Deugnier","year":"1993","unstructured":"Deugnier, Y. M. et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 18, 1363\u20131369 (1993).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18818-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18818-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18818-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T11:06:23Z","timestamp":1751195183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18818-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["18818"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-18818-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,11]]},"assertion":[{"value":"15 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"419"}}